Bioavailability of curcumin: problems and promises.

  title={Bioavailability of curcumin: problems and promises.},
  author={Preetha Anand and Ajaikumar B. Kunnumakkara and Robert A Newman and Bharat Bhushan Aggarwal},
  journal={Molecular pharmaceutics},
  volume={4 6},
Curcumin, a polyphenolic compound derived from dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Phase I clinical trials have shown that curcumin is safe even at high doses (12 g/day) in humans but exhibit poor bioavailability. Major reasons contributing to the low plasma and tissue levels of curcumin appear to be due to poor absorption, rapid metabolism, and rapid systemic elimination. To… 

Figures and Tables from this paper

Curcumin: a review
The main objective of this review article is to overcome or to improve the problems related with curcumin with the help of new technologies or modifications to make a promising therapeutic agent
Bioavailability and Metabolism of Curcuminoids
This review attempts to illuminate the current state of knowledge on the effect of factors on curcuminoid bioavailability through chemical modifications, improved solubility, chemical stability, efficiency of digestive uptake, metabolic processing, and excretion.
Biodistribution of curcumin and its derivatives new aspects for curcumin administration
The finding suggested that free curcumin have the lung accumulation property, which implied lung disease therapeutic effect; and it would also be suitable forCurcumin to explore pulmonary delivery system so as to increase its bioavailability.
Biomedical Applications and Bioavailability of Curcumin—An Updated Overview
A comprehensive overview of the plethora of therapeutic potentials of curcumin, their drawbacks in efficient clinical applications and the recent advancements in improvingCurcumin’s bioavailability for effective use in various biomedical applications is provided.
Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability
This review summarizes recent data on curcumin’s ability to interfere with the multiple cell signaling pathways involved in cell cycle regulation, apoptosis and the migration of several cancer cell types.
The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects?
It is proposed in this review that curcumin's potential as a therapeutic agent may not solely rely on its bioavailability, but rather its medicinal benefits may also arise from its positive influence on gastrointestinal health and function.
Curcumin as a Bioactive Component
The use of nanoencapsulation to improve delivery of curcumin to target tissues suggests that nanodelivery could increase the healing efficiency of cur cumin, and the underlying mechanisms will be discussed.
Oral bioavailability of curcumin: problems and advancements
Recent studies in the design and development of oral delivery systems for curcumin to enhance the solubility and oral bioavailability, including liposomes, nanoparticles and polymeric micelles, phospholipid complexes, and microemulsions are summarized.


Clinical studies with curcumin.
The preliminary results did support the efficacy of curcumin in patients with rheumatoid arthritis, inflammatory eye diseases, inflammatory bowel disease, chronic pancreatitis, psoriasis, hyperlipidemia, and cancers, but it is imperative that well-designed clinical trials, supported by better formulations ofCurcumin or novel routes of administration, be conducted in the near future.
Phase I Clinical Trial of Oral Curcumin
A daily oral dose of 3.6 g of curcumin is advocated for Phase II evaluation in the prevention or treatment of cancers outside the gastrointestinal tract in patients with advanced colorectal cancer refractory to standard chemotherapies.
Anticancer potential of curcumin: preclinical and clinical studies.
Evidence has also been presented to suggest that curcumin can suppress tumor initiation, promotion and metastasis, and Pharmacologically,Curcumin has been found to be safe.
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine
The results suggest that curcumin formulated with phosphatidylcholine furnishes higher systemic levels of parent agent than unformulatedCurcumin.
Dose escalation of a curcuminoid formulation
The tolerance of curcumin in high single oral doses appears to be excellent, and these findings warrant further investigation for its utility as a long-term chemopreventive agent.
Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer
A series of novel curcumin analogues were synthesized and screened for anticancer activity and exhibited neither harmful nor growth-suppressive effects on normal hepatocytes where oncogene products are not activated, suggesting that they may provide effective alternative therapies for the prevention and treatment of some human cancers.
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.
The results suggest that Curcuma extract can be administered safely to patients at doses of up to 2.2 g daily, equivalent to 180 mg of curcumin, and that larger clinical trials ofcurcumin has low oral bioavailability in humans and may undergo intestinal metabolism.
Biotransformation of curcumin through reduction and glucuronidation in mice.
  • M. Pan, T. Huang, J. Lin
  • Biology, Chemistry
    Drug metabolism and disposition: the biological fate of chemicals
  • 1999
The results, together with previous findings, suggest that curcumin-glucuronoside, dihydrocurcumin - glucuronOSide, THC-gloucesteride, and THC are major metabolites ofCurcumin in vivo.